Recombinant Human CD19 Protein, Atto 647N Conjugate Best Seller

R&D Systems, part of Bio-Techne | Catalog # ATM9269

Fc Chimera
R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
ATM9269-020
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Learn more about FluorokinesTM Fluorescent-Labeled Proteins

Source

CHO

Accession #

P15391

Structure / Form

Disulfide-linked homodimer, labeled with Atto 647N via amines


Excitation Wavelength: 647 nm
Emission Wavelength: 667 nm

Conjugate

ATTO 647N (Excitation= 647 nm, Emission= 667 nm)

Applications

Bioactivity

View all CD19 Proteins and Enzymes »

Product Specifications

Source

Chinese Hamster Ovary cell line, CHO-derived human CD19 protein
Human CD19
(Glu21-Lys291)
Accession # P15391		 IEGRMD Human IgG1
(Pro100-Lys330)
N-terminus C-terminus

Purity

>90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<1.0 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Glu21

Predicted Molecular Mass

57 kDa

SDS-PAGE

77-92 kDa, under reducing conditions

Activity

Measured by flow cytometry for its ability to bind anti-Human CD19 Monoclonal Antibody conjugated fluorescent beads.

Scientific Data Images for Recombinant Human CD19 Protein, Atto 647N Conjugate

Detection of CD19 construct on human CART cells

Human PBMC CD4+ and CD8+ T cells were either (A) transduced or (B) not transduced (negative control) with a Human CD19 CAR and then cultured for 11 days. Cells were washed twice with 2mL 1x PBS then stained with a viability dye for 15-30 min at room temp in the dark. Human block (1-001-1) was added during the viability stain to block Fc receptors. Cells were washed twice with Flow Cytometry Staining Buffer (FC001) then stained with Human CD4 PE-Cy7-conjugated Antibody and rhCD19 Atto 647N-conjugated protein (ATM9269) for 25 min at room temp in the dark. Staining was performed using our staining membrane proteins protocol.
Recombinant Human CD19 Protein, Atto 647N Conjugate SDS-PAGE

Recombinant Human CD19 Protein, Atto 647N Conjugate SDS-PAGE.

2 μg/lane of Recombinant Human CD19 Fc Chimera Atto 647N (ATM9269) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 77-92 kDa and 154-184 kDa, respectively.

Formulation, Preparation and Storage

ATM9269
Formulation Supplied as a 0.2 μm filtered solution in PBS with BSA as a carrier protein.
Shipping The product is shipped with dry ice or equivalent. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Protect from light. Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 6 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after opening.
  • 3 months, -20 to -70 °C under sterile conditions after opening.

Background: CD19

CD19 is a 95 kDa transmembrane glycoprotein that plays a central role in B cell activation and humoral immune responses (1, 2). Mature human CD19 consists of a 272 amino acid (aa) extracellular domain (ECD) with two Ig-like domains, a 22 aa transmembrane segment, and a 243 aa cytoplasmic domain (3). Within the ECD, human CD19 shares 57% amino acid sequence identity with mouse and rat CD19. CD19 is expressed throughout B cell development from pre-B cells to mature B cells, and it is commonly used as a B cell lineage marker (1). It is required for the responsiveness of mature B cell to antigen stimulation, germinal center development, and antibody affinity maturation (4, 5). CD19 associates with the B cell antigen receptor (BCR), CD81, CD38, CD21, CD22, and IFITM1/CD225/Leu13, (6-9). These associations enable CD19 to amplify B cell signaling (7, 9-12) and reduce the threshold for antigen stimulation through the BCR (13). CD19 polymorphisms and up-regulation can lead to the development of autoimmunity by promoting autoantibody production (2).

References

  1. Wang, K. et al. (2012) Exp. Hematol. Oncol. 1:36.
  2. Tedder, T.F. et al. (1997) Immunity 6:107.
  3. Tedder, T.F. and C.M. Isaacs (1989) J. Immunol. 143:712.
  4. Rickert, R.C. et al. (1995) Nature 376:352.
  5. Engel, P. et al. (1995) Immunity 3:39.
  6. Vences-Catalan, F. et al. (2012) J. Immunol. 137:48.
  7. Deaglio, S. et al. (2007) Blood 109:5390.
  8. Bradbury, L. et al. (1992) J. Immunol. 149:2841.
  9. Krop, I. et al. (1996) J. Immunol. 157:48.
  10. O'Rourke, L.M. et al. (1998) Immunity 8:635.
  11. Buhl, A.M. et al. (1997) J. Exp. Med. 186:1897.
  12. Sato, S. et al. (1995) Proc. Natl. Acad. Sci. USA 92:11558.
  13. Carter, R.H. and D.T. Fearon (1992) Science 256:105.

Alternate Names

CD19, CVID3, Leu-12

Entrez Gene IDs

930 (Human); 12478 (Mouse); 365367 (Rat); 397669 (Porcine); 607898 (Canine); 102145514 (Cynomolgus Monkey); 100147468 (Equine)

Gene Symbol

CD19

UniProt

P15391 (Human)

Additional CD19 Products

Product Documents for Recombinant Human CD19 Protein, Atto 647N Conjugate

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Download SDS

Product Specific Notices for Recombinant Human CD19 Protein, Atto 647N Conjugate

For research use only

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.